Vivos Therapeutics (VVOS) Change in Account Payables (2020 - 2026)
Vivos Therapeutics (VVOS) reported Change in Account Payables of $318000.0 for Q1 2026, up 191.74% year-over-year from $109000.0 in Q1 2025, and up 175.0% on a QoQ basis from -$424000.0 in Q4 2025.
Vivos Therapeutics (VVOS) has 7 years of Change in Account Payables data on file, last reported at $318000.0 in Q1 2026.
- Quarterly Change in Account Payables rose 191.74% year-over-year to $318000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $733000.0 (up 156.69% YoY) and the FY2025 annual result came in at $524000.0, up 150.0% from the prior year.
- Change in Account Payables climbed to $318000.0 in Q1 2026 per VVOS's latest filing, from -$424000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $767000.0 in Q4 2022 and bottomed at -$953000.0 in Q3 2024.
- The 5-year median for Change in Account Payables is $109000.0 (2025), against an average of $59941.2.
- The widest annual swing landed in 2024, when Change in Account Payables jumped 321.43%; it then slumped 2027.27% in 2025.
- Tracing VVOS's Change in Account Payables over 5 years: stood at $767000.0 in 2022, then fell by 19.69% to $616000.0 in 2023, then tumbled by 96.43% to $22000.0 in 2024, then tumbled by 2027.27% to -$424000.0 in 2025, then soared by 175.0% to $318000.0 in 2026.
- Per Business Quant, the three latest VVOS Change in Account Payables figures stand at $318000.0 (Q1 2026), -$424000.0 (Q4 2025), and $340000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | - |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | -198.00 Mn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | - |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 221.00 Mn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 56.90 Mn |
| 10 | Vivos Therapeutics | 9.87 Mn | 7.64 Mn | 3.06 Mn | 318,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 318,000.00 |
| Mar 31, 2026 | 318,000.00 |
| Dec 31, 2025 | -424,000.00 |
| Dec 31, 2025 | -424,000.00 |
| Sep 30, 2025 | 340,000.00 |
| Sep 30, 2025 | 340,000.00 |
| Jun 30, 2025 | 499,000.00 |
| Jun 30, 2025 | 499,000.00 |
| Mar 31, 2025 | 109,000.00 |
| Mar 31, 2025 | 109,000.00 |
| Dec 31, 2024 | 22,000.00 |
| Dec 31, 2024 | 22,000.00 |
| Sep 30, 2024 | -953,000.00 |
| Sep 30, 2024 | -953,000.00 |
| Jun 30, 2024 | -471,000.00 |
| Jun 30, 2024 | -471,000.00 |
| Mar 31, 2024 | 354,000.00 |
| Mar 31, 2024 | 354,000.00 |
| Dec 31, 2023 | 616,000.00 |
| Dec 31, 2023 | 616,000.00 |
| Sep 30, 2023 | 204,000.00 |
| Sep 30, 2023 | 204,000.00 |
| Jun 30, 2023 | -170,000.00 |
| Jun 30, 2023 | -170,000.00 |
| Mar 31, 2023 | 84,000.00 |
| Mar 31, 2023 | 84,000.00 |
| Dec 31, 2022 | 767,000.00 |
| Dec 31, 2022 | 767,000.00 |
| Sep 30, 2022 | -607,000.00 |
| Sep 30, 2022 | -607,000.00 |
| Jun 30, 2022 | 373,000.00 |
| Jun 30, 2022 | 373,000.00 |
| Mar 31, 2022 | -42,000.00 |
| Mar 31, 2022 | -42,000.00 |
| Dec 31, 2021 | 220,000.00 |
| Dec 31, 2021 | 220,000.00 |
| Sep 30, 2021 | 902,000.00 |
| Sep 30, 2021 | 902,000.00 |
| Jun 30, 2021 | 426,000.00 |
| Jun 30, 2021 | 426,000.00 |
| Mar 31, 2021 | -1.41 Mn |
| Mar 31, 2021 | -1.41 Mn |
| Dec 31, 2020 | -720,787.00 |
| Dec 31, 2020 | -720,787.00 |
| Sep 30, 2020 | 220,467.00 |
| Sep 30, 2020 | 220,467.00 |
| Jun 30, 2020 | -562,760.00 |
| Jun 30, 2020 | -562,760.00 |
| Mar 31, 2020 | 789,080.00 |
| Mar 31, 2020 | 789,080.00 |